Advertisement

Drug Safety

, Volume 28, Issue 1, pp 67–80 | Cite as

Incidence and Possible Causes of Prescribing Potentially Hazardous/Contraindicated Drug Combinations in General Practice

  • Yen-Fu ChenEmail author
  • Anthony J. Avery
  • Karen E. Neil
  • Christine Johnson
  • Michael E. Dewey
  • Ivan H. Stockley
Original Research Article

Abstract

Background: Preventing the use of medications where there is the potential for serious drug-drug interactions or drug-disease interactions (contraindications) is essential to ensure patient safety. Previous studies have looked at the incidence of prescribing contraindicated drug combinations, but little is known about the underlying reasons for the co-prescribing events. The objectives of this study were to estimate the incidence of prescribing contraindicated drug combinations in general practice and to explore the clinical context, possible causes and potential systems failures leading to their occurrence.

Methods: A list of contraindicated drug combinations was compiled according to established references. A search of computerised patient medication records was performed, followed by detailed chart review and assessment. The patient records from four general practices in an area of England were searched for a period of 1 year (1 June 1999–31 May 2000) to identify contraindicated drug combinations. All patients registered with the four participating practices during the study period were included (estimated n = 37 940). Medical records of the cases identified by the computer search were reviewed in detail and relevant information was extracted. Each case was then independently assessed by a pharmacist and a physician who judged whether the co-prescribing was justified and whether it was associated with an adverse drug event. Proximal causes and potential systems failures were suggested for each co-prescribing event.

Main outcome measures and results: Fourteen patients with potential drug-drug interactions and 50 patients with potential drug-disease interactions were identified. Overall, these represent an incidence of 1.9 per 1000 patient-years (95% CI 1.5, 2.3) or 4.3 per 1000 patients being concurrently prescribed ≥2 drugs per year (95% CI 3.2, 5.4). 62 cases involving 63 co-prescribing events were reviewed. Two-thirds of these events involved medications that were initiated by hospital doctors. Awareness of the potential drug-drug or drug-disease interactions was documented in one-third of the events at the time of initial co-prescribing. Within the study period, the co-prescribing was judged to be not justified in 44 events (70%). Potential drug-drug interactions possibly resulted in two adverse drug events. The majority of contraindicated co-prescribing related to drug-disease interactions involved the use of propranolol or timolol eye drops for patients receiving bronchodilators and the use of amiodarone for patients receiving levothyroxine sodium.

Conclusion: The prescribing of contraindicated drug combinations was relatively rare in this study. Multiple possible causes and systems failures were identified and could be used to develop strategies for the prevention of prescribing errors involving contraindicated drug combinations in primary care.

Keywords

Amiodarone Sumatriptan Drug Combination Adverse Drug Event Community Pharmacist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

This study was funded by National Health Services R & D Support Funding for Primary Care, United Kingdom. We are grateful to the general practitioners and staff in the participating practices for their co-operation. At the time of manuscript revision, Yen-Fu Chen is affiliated with the Department of Public Health and Epidemiology, University of Birmingham and Michael Dewey with the Institute of Psychiatry, King’s College London, UK. The authors have no conflicts of interest that are directly relevant to the content of this study.

References

  1. 1.
    Jankel CA, Speedie SM. Detecting drug interactions: a review of the literature. DICP 1990; 24: 982–9PubMedGoogle Scholar
  2. 2.
    Linnarsson R. Drug interactions in primary health care. Scand J Prim Health Care 1993; 11: 181–6PubMedCrossRefGoogle Scholar
  3. 3.
    Sipilä J, Klaukka T, Martikainen J, et al. Occurrence of potentially harmful drug combinations among Finnish primary care patients. Int Pharm J 1995; 9: 104–7Google Scholar
  4. 4.
    Stevens RG, Balon D. Detection of hazardous drug/drug interactions in a community pharmacy and subsequent intervention. Int J Pharm Pract 1997; 5: 142–8CrossRefGoogle Scholar
  5. 5.
    Rosholm JU, Bjerrum L, Halls J, et al. Polypharmacy and the risk of drug-drug interactions among Danish elderly. Dan Med Bull 1998; 45: 210–3PubMedGoogle Scholar
  6. 6.
    Halkin H, Katzir I, Kurman I, et al. Preventing drug interactions by online prescription screening in community pharmacies and medical practices. Clin Pharmacol Ther 2001; 69: 260–5PubMedCrossRefGoogle Scholar
  7. 7.
    Merlo J, Liedholm H, Lindblad U, et al. Prescriptions with potential drug interactions dispensed at Swedish pharmacies in January 1999: cross sectional study. BMJ 2001; 323: 427–8PubMedCrossRefGoogle Scholar
  8. 8.
    Evans JMM, Hayes JL, Lipworth BJ, et al. Potentially hazardous co-prescribing of β-adrenoceptor antagonists and agonists in the community. Br J Gen Pract 1996; 46: 423–5PubMedGoogle Scholar
  9. 9.
    Valuck RJ, Perlman JI, Anderson C, et al. Co-prescribing of medications used to treat obstructive lung disease, congestive heart failure and depression among users of topical beta blockers: estimates from three US Veterans Affairs Medical Centers. Pharmacoepidemiol Drug Saf 2001; 10: 511–6PubMedCrossRefGoogle Scholar
  10. 10.
    Hanlon JT, Schmader KE, Boult C, et al. Use of inappropriate prescription drugs by older people. J Am Geriatr Soc 2002; 50: 26–34PubMedCrossRefGoogle Scholar
  11. 11.
    Hartshorn EA. Significance and interpretation of drug interaction information. Drug Intell Clin Pharm 1970; 4: 173Google Scholar
  12. 12.
    Stockley IH. Drug interactions. 5th ed. London: Pharmaceutical Press, 1999Google Scholar
  13. 13.
    Hansten PD, Horn JR. Hansten and Horn’s managing clinically important drug interactions. Vancouver (WA): Applied Therapeutics Inc, 1998Google Scholar
  14. 14.
    Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239–45PubMedCrossRefGoogle Scholar
  15. 15.
    Leape LL, Bates DW, Cullen DJ, et al. Systems analysis of adverse drug events. JAMA 1995; 274: 35–43PubMedCrossRefGoogle Scholar
  16. 16.
    Joint Formulary Committee. British National Formulary 39. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2000Google Scholar
  17. 17.
    Newman CM, Price A, Davies DW, et al. Amiodarone and the thyroid: a practical guide to the management of thyroid dysfunction induced by amiodarone therapy. Heart 1998; 79: 121–7Google Scholar
  18. 18.
    Loh K-C. Amiodarone-induced thyroid disorders: a clinical review. Postgrad Med J 2000; 76: 133–40PubMedCrossRefGoogle Scholar
  19. 19.
    Smalley W, Shatin D, Wysowski DK, et al. Contraindicated use of cisapride: impact of Food and Drug Administration regulatory action. JAMA 2000; 284: 3036–9PubMedCrossRefGoogle Scholar
  20. 20.
    Jones JK, Fife D, Curkendall S, et al. Coprescribing and codispensing of cisapride and contraindicated drugs. JAMA 2001; 286: 1607–9PubMedCrossRefGoogle Scholar
  21. 21.
    Weatherby LB, Walker AM, Fife D, et al. Contraindicated medications dispensed with cisapride: temporal trends in relation to the sending of ‘Dear Doctor’ letters. Pharmacoepidemiol Drug Saf 2001; 10: 211–8PubMedCrossRefGoogle Scholar
  22. 22.
    Raschetti R, Maggini M, Da Cas R, et al. Time trends in the coprescribing of cisapride and contraindicated drugs in Umbria, Italy. JAMA 2001; 285: 1840–1PubMedCrossRefGoogle Scholar
  23. 23.
    Jones FLJ, Ekberg NL. Exacerbation of obstructive airway disease by timolol [letter]. JAMA 1980; 244: 2730PubMedCrossRefGoogle Scholar
  24. 24.
    Schoene RB, Martin TR, Charan NB, et al. Timolol-induced bronchospasm in asthmatic bronchitis. JAMA 1981; 245: 1460–1PubMedCrossRefGoogle Scholar
  25. 25.
    Fraunfelder FT, Barker AF. Respiratory effects of timolol [letter]. N Engl J Med 1984; 311: 1441PubMedGoogle Scholar
  26. 26.
    Schoene RB, Abuan T, Ward RL, et al. Effects of topical betaxolol, timolol, and placebo on pulmonary function in asthmatic bronchitis. Am J Ophthalmol 1984; 97: 86–92PubMedGoogle Scholar
  27. 27.
    Diggory P, Heyworth P, Chau G, et al. Unsuspected bronchospasm in association with topical timolol -a common problem in elderly people: can we easily identify those affected and do cardioselective agents lead to improvement? Age Ageing 1994; 23: 17–21PubMedCrossRefGoogle Scholar
  28. 28.
    Diggory P, Cassels-Brown A, Vail A, et al. Avoiding unsuspected respiratory side-effects of topical timolol with cardioselective or sympathomimetic agents. Lancet 1995; 345: 1604–6PubMedCrossRefGoogle Scholar
  29. 29.
    Good CB. Topical beta-blockers in patients with co-existing conditions: is this a cause for concern? [editorial]. Pharmacoepidemiol Drug Saf 2001; 10: 509–10PubMedCrossRefGoogle Scholar
  30. 30.
    Mageean RJ. Study of ‘discharge communications’ from hospital. BMJ 1986; 293: 1283–4PubMedCrossRefGoogle Scholar
  31. 31.
    Penney TM. Delayed communication between hospitals and general practitioners: where does the problem lie? BMJ 1988; 297: 28–9PubMedCrossRefGoogle Scholar
  32. 32.
    Williams EI, Fitton F. General practitioner response to elderly patients discharged from hospital. BMJ 1990; 300: 159–61PubMedCrossRefGoogle Scholar
  33. 33.
    Coleman A, Ricketts L, Teal S, et al. An audit of hospital discharge and outpatient information from a primary care perspective. J Soc Adm Pharm 2001; 18: 226–31Google Scholar
  34. 34.
    Zermansky AG. Who controls repeats? Br J Gen Pract 1996; 46: 643–7PubMedGoogle Scholar
  35. 35.
    Bradley CP, Fraser A. Repeat prescribing. Br J Gen Pract 1997; 47: 255–6PubMedGoogle Scholar
  36. 36.
    Magnus D, Rodgers S, Avery AJ. GPs’ views on computerised drug interaction alerts: questionnaire survey. J Clin Pharm Ther 2002; 27: 377–82PubMedCrossRefGoogle Scholar
  37. 37.
    Hazlet TK, Lee TA, Hansten PD, et al. Performance of community pharmacy drug interaction software. J Am Pharm Assoc 2001; 41: 200–4Google Scholar
  38. 38.
    Pringle M, Ward P, Chilvers C. Assessment of the completeness and accuracy of computer medical records in four practices committed to recording data on computer. Br J Gen Pract 1995; 45: 537–41PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  • Yen-Fu Chen
    • 1
    Email author
  • Anthony J. Avery
    • 2
  • Karen E. Neil
    • 2
  • Christine Johnson
    • 3
  • Michael E. Dewey
    • 1
  • Ivan H. Stockley
    • 4
  1. 1.Trent Institute for Health Services ResearchUniversity of NottinghamNottinghamUK
  2. 2.Division of Primary CareUniversity of NottinghamNottinghamUK
  3. 3.Beeston Primary Care Research GroupNottinghamUK
  4. 4.University of Nottingham Medical SchoolNottinghamUK

Personalised recommendations